Baxdrostat by AstraZeneca shows significant blood pressure reduction in Phase III trial, advancing treatment for resistant hypertension. Promising results showcase its safety and effectiveness.
AstraZeneca's SEC Form 6-K reveals promising results for Datroway in metastatic triple-negative breast cancer, showing significant survival improvements in patients not eligible for immunotherapy.
AstraZeneca's report highlights Tezspire's EU approval for CRSwNP, showcasing significant trial results and market potential. A game-changer for 320M affected globally.
Explore AstraZeneca's latest Form 6-K report detailing promising Saphnelo trial results for SLE, highlighting innovative treatment options and future regulatory steps.
This SEC Form 6-K reveals AstraZeneca's Phase III results for Gefurulimab in treating gMG, highlighting significant improvements in daily living activities and a solid safety profile.
Explore AstraZeneca's latest report on anselamimab's Phase III trial for AL amyloidosis, highlighting key findings and future steps.
AstraZeneca PLC announces the approval of Datroway for advanced EGFR-mutated lung cancer, highlighting clinical trial success and strategic collaboration with Daiichi Sankyo.
AstraZeneca's 6-K filing reveals EU approval for Calquence in CLL, showcasing superior trial results and market potential.
AstraZeneca's report highlights Imfinzi's EU approval for muscle-invasive bladder cancer, showcasing significant efficacy from clinical trials. Key insights reveal its potential to redefine treatment standards.
AstraZeneca's latest SEC Form 6-K reveals promising results from the DESTINY-Breast11 trial, highlighting Enhertu's potential to redefine treatment for high-risk HER2-positive breast cancer patients.
Discover AstraZeneca's financial report on Calquence's EU approval for untreated CLL, highlighting significant trial results and market potential.
AstraZeneca's SEC report reveals the discontinuation of the CAPItello-280 trial for mCRPC. Discover the reasons, trial details, and future strategies in prostate cancer treatment.